MRK

MRK (PF3D7_1014400) is a Plasmodium falciparum cyclin-dependent kinase most similar to human CDK7/MO15 that functions within the parasite nucleus to phosphorylate RNA polymerase II and DNA replication substrates (PMID:8944769, PMID:20332005). As a recombinant enzyme it displays intrinsic histone H1 kinase and autophosphorylation activity, forms a stable complex with human cyclin H that stimulates its activity, and is refractory to the classical CDK inhibitors olomoucine and roscovitine while being inhibited by human p21(CIP1) but not p16(INK4) (PMID:10717301, PMID:11700040). Its endogenous activator is PfMAT1, whose C-terminal domain physically associates with and stimulates MRK in a cyclin-dependent manner and confers substrate specificity to the kinase complex (PMID:16737745, PMID:20332005). Functionally, MRK phosphorylates the RNA polymerase II CTD but does not phosphorylate PfPK5, distinguishing it as a CTD kinase rather than a CDK-activating kinase, and phosphorylates the DNA replication proteins PfRFC-5 and PfMCM6 identified as interactors (PMID:16737745, PMID:20332005). Active-site mutations S138K and F143L render MRK constitutively active independently of cyclin or PfMAT1 (PMID:16737745). The kinase is transcribed predominantly in gametocytes yet was identified as likely essential for erythrocytic schizogony (PMID:8944769, PMID:22127061).

1. 1996 Medium

   Establishing that P. falciparum encodes a CDK7/MO15-like kinase defined MRK as a candidate cell-cycle/transcription regulator and set its sequence and expression baseline.

   Evidence Gene cloning, sequence analysis, Southern blotting, chromosomal separation, and stage-specific Northern blot

   PMID:8944769

   Open questions at the time

   • No functional or enzymatic activity demonstrated
   • Role of the two unique inserts near the cyclin-binding and T-loop regions unknown
   • Predominant gametocyte transcription not reconciled with a proposed schizogony role
2. 2000 High

   Reconstituting recombinant MRK demonstrated it is a bona fide kinase whose activity depends on a cyclin partner, answering whether the CDK7-like sequence corresponds to an active enzyme.

   Evidence Recombinant 6xHis MRK in E. coli with histone H1 kinase, autophosphorylation, cyclin H complex formation, and inhibitor-profiling assays

   PMID:10717301

   Open questions at the time

   • Endogenous parasite cyclin partner not identified
   • Physiological substrates beyond histone H1 unknown
   • Resistance to olomoucine/roscovitine unexplained mechanistically
3. 2001 Medium

   Differential inhibition by human p21(CIP1) versus p16(INK4) provided a pharmacological handle distinguishing MRK regulation from other CDK classes.

   Evidence In vitro kinase inhibition assays with recombinant human CDK inhibitors

   PMID:11700040

   Open questions at the time

   • No endogenous parasite inhibitor identified
   • Single in vitro method without cellular validation
4. 2006 High

   Identifying PfMAT1 as an activator and testing substrate preference resolved whether MRK acts as a CTD kinase or a CDK-activating kinase.

   Evidence In vitro kinase assays with PfMAT1, RNA Pol II CTD and PfPK5 substrate assays, and S138K/F143L active-site mutagenesis

   PMID:16737745

   Open questions at the time

   • In vivo relevance of CTD phosphorylation not shown
   • Structural basis of constitutive activation by S138K/F143L unresolved
5. 2010 High

   Mapping the MRK–PfMAT1 interaction, nuclear co-localization, and identifying PfRFC-5 and PfMCM6 as substrates connected MRK to both transcription and DNA replication machinery.

   Evidence Co-immunoprecipitation, GFP/RFP immunofluorescence, bacterial two-hybrid screen of a P. falciparum cDNA library, and in vitro phosphorylation assays

   PMID:20332005

   Open questions at the time

   • Physiological consequence of PfRFC-5/PfMCM6 phosphorylation in replication not demonstrated
   • Two-hybrid interactions not all validated in parasites
   • Full endogenous activating cyclin still undefined
6. 2011 Low

   A kinome-wide screen placed MRK among kinases essential for asexual blood-stage growth, elevating its interest as a drug target.

   Evidence Kinome-wide reverse genetics screen scoring genes for essentiality in erythrocytic schizogony

   PMID:22127061

   Open questions at the time

   • Essentiality inferred from screen, not a dedicated conditional knockout of MRK
   • No mechanistic link between the essential phenotype and MRK's CTD/replication substrate activities

• The endogenous parasite cyclin that activates MRK in vivo, and how its CTD-kinase and replication-substrate activities integrate to make it essential, remain undefined.
• No native activating cyclin identified for MRK
• No conditional-knockout mechanistic dissection of the essential phenotype
• No structure of the MRK–PfMAT1 complex